← Back to headlines
Halozyme Therapeutics Misses EPS, Beats Revenue Estimates
Halozyme Therapeutics reported a non-GAAP EPS of -$0.24, missing estimates, but its revenue of $451M surpassed expectations.
17 Feb, 21:04 — 17 Feb, 21:04
ℹOnly 1 source covers this story
Read at source (1 outlet)
Related Stories
Investment Outlook: Dividend Aristocrats Poised for 2026 Rebound
17m ago
Stock Market Today, Feb. 20: CoreWeave Falls After Blue Owl Data Center Financing Failure Raises Funding Concerns
57m ago
Why CoreWeave Was Plunging To End the Week Today
57m ago
Costco Price Target Raised by Evercore ISI and Citi After Q2 Beat
57m ago